UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer

J. McKeon, E. Daniels, A. Halstead, C. Machado, S. Potter, T. Strawson-Smith, A. Okines, S. Mcintosh, H. Tovey, T. Robinson, H. Abdallah, S. Ahmed, N. Ainsworth, A. Akhtar, M. Amaya, C. Archer, A. Armstrong, O. Ayodele, A. Ayyad, M. Azhar, K. Ball, B. Baraka, H. Barot, U. Barthakur, A. Borley, R. Bowen, F. Britton, H. Chapman, H. Cook, E. Copson, K. Crawford, N. Cresti, B. Crook, R. Cutress, L. Drewett, K.H. El-Shakankery, L. Glanville, R. Gul, A. Guppy, L. Gurung, V. Harding, C. Harper-Wynne, L. Hennah, S. Ho, J. Howells, T. Irfan, C. Iwu, E. Johnston, S. Khan, J. King, P. Koliou, A. Konstantis, C. Kruppa, A. Lewis, P. Lowdon, T. Lucas, A.L. Smith, K. McAdams, H. McKenzie, C. Michie, T. Nawarathna, D. Nelmes, O. Oikonomidou, O. Omokhodion, C. O’Neill, A. Percival, C. Pow, S. Rana, D. Rea, S. Rehman, H. Sarwar, S. Seymour, A. Shaheen, A. Sheri, R. Simcock, S. Spensley, M.H. Syed Khaja, A. Thomson, L. Uden, L. Walkington, L. Watts, H. Whydle, H. Yusof

Open source

DOI: 10.1016/j.esmorw.2025.100664
Published: 2026-03
Container: ESMO Real World Data and Digital Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmorw.2025.100664,
title = {UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer},
author = {J. McKeon and E. Daniels and A. Halstead and C. Machado and S. Potter and T. Strawson-Smith and A. Okines and S. Mcintosh and H. Tovey and T. Robinson and H. Abdallah and S. Ahmed and N. Ainsworth and A. Akhtar and M. Amaya and C. Archer and A. Armstrong and O. Ayodele and A. Ayyad and M. Azhar and K. Ball and B. Baraka and H. Barot and U. Barthakur and A. Borley and R. Bowen and F. Britton and H. Chapman and H. Cook and E. Copson and K. Crawford and N. Cresti and B. Crook and R. Cutress and L. Drewett and K.H. El-Shakankery and L. Glanville and R. Gul and A. Guppy and L. Gurung and V. Harding and C. Harper-Wynne and L. Hennah and S. Ho and J. Howells and T. Irfan and C. Iwu and E. Johnston and S. Khan and J. King and P. Koliou and A. Konstantis and C. Kruppa and A. Lewis and P. Lowdon and T. Lucas and A.L. Smith and K. McAdams and H. McKenzie and C. Michie and T. Nawarathna and D. Nelmes and O. Oikonomidou and O. Omokhodion and C. O’Neill and A. Percival and C. Pow and S. Rana and D. Rea and S. Rehman and H. Sarwar and S. Seymour and A. Shaheen and A. Sheri and R. Simcock and S. Spensley and M.H. Syed Khaja and A. Thomson and L. Uden and L. Walkington and L. Watts and H. Whydle and H. Yusof},
year = {2026},
journal = {ESMO Real World Data and Digital Oncology},
doi = {10.1016/j.esmorw.2025.100664},
url = {https://doi.org/10.1016/j.esmorw.2025.100664}
}

RIS

TY  - JOUR
TI  - UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer
AU  - J. McKeon
AU  - E. Daniels
AU  - A. Halstead
AU  - C. Machado
AU  - S. Potter
AU  - T. Strawson-Smith
AU  - A. Okines
AU  - S. Mcintosh
AU  - H. Tovey
AU  - T. Robinson
AU  - H. Abdallah
AU  - S. Ahmed
AU  - N. Ainsworth
AU  - A. Akhtar
AU  - M. Amaya
AU  - C. Archer
AU  - A. Armstrong
AU  - O. Ayodele
AU  - A. Ayyad
AU  - M. Azhar
AU  - K. Ball
AU  - B. Baraka
AU  - H. Barot
AU  - U. Barthakur
AU  - A. Borley
AU  - R. Bowen
AU  - F. Britton
AU  - H. Chapman
AU  - H. Cook
AU  - E. Copson
AU  - K. Crawford
AU  - N. Cresti
AU  - B. Crook
AU  - R. Cutress
AU  - L. Drewett
AU  - K.H. El-Shakankery
AU  - L. Glanville
AU  - R. Gul
AU  - A. Guppy
AU  - L. Gurung
AU  - V. Harding
AU  - C. Harper-Wynne
AU  - L. Hennah
AU  - S. Ho
AU  - J. Howells
AU  - T. Irfan
AU  - C. Iwu
AU  - E. Johnston
AU  - S. Khan
AU  - J. King
AU  - P. Koliou
AU  - A. Konstantis
AU  - C. Kruppa
AU  - A. Lewis
AU  - P. Lowdon
AU  - T. Lucas
AU  - A.L. Smith
AU  - K. McAdams
AU  - H. McKenzie
AU  - C. Michie
AU  - T. Nawarathna
AU  - D. Nelmes
AU  - O. Oikonomidou
AU  - O. Omokhodion
AU  - C. O’Neill
AU  - A. Percival
AU  - C. Pow
AU  - S. Rana
AU  - D. Rea
AU  - S. Rehman
AU  - H. Sarwar
AU  - S. Seymour
AU  - A. Shaheen
AU  - A. Sheri
AU  - R. Simcock
AU  - S. Spensley
AU  - M.H. Syed Khaja
AU  - A. Thomson
AU  - L. Uden
AU  - L. Walkington
AU  - L. Watts
AU  - H. Whydle
AU  - H. Yusof
PY  - 2026
JO  - ESMO Real World Data and Digital Oncology
DO  - 10.1016/j.esmorw.2025.100664
UR  - https://doi.org/10.1016/j.esmorw.2025.100664
ER  -

APA

McKeon, J., Daniels, E., Halstead, A., Machado, C., Potter, S., Strawson-Smith, T., Okines, A., Mcintosh, S., Tovey, H., Robinson, T., Abdallah, H., Ahmed, S., Ainsworth, N., Akhtar, A., Amaya, M., Archer, C., Armstrong, A., Ayodele, O., Ayyad, A., Azhar, M., Ball, K., Baraka, B., Barot, H., Barthakur, U., Borley, A., Bowen, R., Britton, F., Chapman, H., Cook, H., Copson, E., Crawford, K., Cresti, N., Crook, B., Cutress, R., Drewett, L., El-Shakankery, K., Glanville, L., Gul, R., Guppy, A., Gurung, L., Harding, V., Harper-Wynne, C., Hennah, L., Ho, S., Howells, J., Irfan, T., Iwu, C., Johnston, E., Khan, S., King, J., Koliou, P., Konstantis, A., Kruppa, C., Lewis, A., Lowdon, P., Lucas, T., Smith, A., McAdams, K., McKenzie, H., Michie, C., Nawarathna, T., Nelmes, D., Oikonomidou, O., Omokhodion, O., O’Neill, C., Percival, A., Pow, C., Rana, S., Rea, D., Rehman, S., Sarwar, H., Seymour, S., Shaheen, A., Sheri, A., Simcock, R., Spensley, S., Khaja, M. S., Thomson, A., Uden, L., Walkington, L., Watts, L., Whydle, H., & Yusof, H. (2026). UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer. ESMO Real World Data and Digital Oncology. https://doi.org/10.1016/j.esmorw.2025.100664

Source records

crossref · retrieved 2026-09-25T16:19:55.392Z